'Fund raising approved' is not enough to analyse a capital event. A qualified institutional placement and a preferential issue can both add equity capital, but the buyers, pricing process, dilution profile and governance questions can be very different.

Ask who is receiving the securities

A QIP is generally aimed at qualified institutional buyers under its governing framework, while a preferential issue allocates securities to identified allottees subject to the stated terms and approvals. The distinction is useful because the investor should understand not just how much capital is raised, but whose economic and voting interest is increasing.

Read the names or categories of proposed allottees where disclosed, their relationship to the company, and any resulting change in shareholding or control. Promoter participation can be relevant, but it does not answer whether the price and use of capital are fair to all holders.

Dilution is an economic question

Calculate the new securities relative to existing shares, then ask what the money is expected to earn. Dilution that funds a high-return, well-defined project can be rational. Dilution that fills a recurring cash gap or finances an unclear acquisition requires a more sceptical view.

Where warrants are involved, note the exercise price, timeline, up-front payment and what conversion would do to shares outstanding. A headline raise may represent only part of the eventual dilution.

Keep the approval and use-of-proceeds path visible

Board approval, shareholder approval, pricing, allotment and use of funds can all create later disclosures. The event note should record which step has happened and which remains. A proposed issue is different from an allotted issue; an allotted issue is different from capital that has been deployed productively.

Do not label every raise bullish or bearish. The task is to connect price, recipients, capital need and eventual operating evidence.

Research checklist

  • Who receives the securities, and are they related to the promoter group?
  • What is the issue price and prospective share dilution?
  • Are there warrants or later conversion rights?
  • What is the stated use of proceeds and what will verify it?

This guide is educational information, not a recommendation, investment advice or a substitute for reading the underlying disclosure.